Sermorelin for Recovery: Off-Label Evidence, Protocols, and Monitoring

What was sermorelin approved for?

Sermorelin acetate is a 29-amino-acid analogue of human growth hormone-releasing hormone, the shortest synthetic peptide with the full biological activity of GHRH. It is not growth hormone itself [8].

It reached the market as Geref under two FDA applications. A 0.05 mg/ampule product was approved on December 28, 1990 for evaluating the pituitary's ability to secrete growth hormone, and 0.5 mg and 1 mg vials were approved on September 26, 1997 for treating idiopathic growth hormone deficiency in children with growth failure [4]. Geref was not approved for adults, anti-aging, weight loss or athletic performance [4].

The manufacturer discontinued Geref in 2008 and asked FDA to withdraw the applications. FDA withdrew both approvals effective June 18, 2009, and in March 2013 determined that Geref was not withdrawn from sale for reasons of safety or effectiveness [4].

Does sermorelin help recovery?

The human studies described on this page measured growth and hormone outcomes, plus a few strength measures in one small study. None measured recovery after injury, surgery or training.

Reviews point the same way. A 2026 review of therapeutic peptides in orthopaedics lists sermorelin among growth hormone secretagogues described as activating IGF-1 signalling and satellite cell repair, but notes that preclinical studies are promising while clinical trials are lacking [1]. A 2026 review of approved and unapproved peptides in sports medicine notes that many unapproved peptides show favourable tissue repair in animal models while rigorous human safety data are scarce [2]. A third review, on peptide use in sport and bodybuilding, notes that clinical evidence is limited and that most published studies examine therapeutic uses under controlled dosing, rather than the combined or higher-dose protocols described in bodybuilding [3].

What sermorelin does to growth hormone

Sermorelin stimulates growth hormone release from the pituitary. In healthy men given an intravenous dose, the peptide was eliminated quickly while growth hormone remained elevated for about three hours [8][11].

In a study of 30 healthy men aged 19 to 43, an intravenous dose as low as 0.25 micrograms/kg produced measurable growth hormone release, with maximal release at 1 to 2 micrograms/kg and mean peaks around 90 mU/L [11].

What the human studies actually measured

One year of treatment in children

The largest study was an open-label, multicenter, one-year trial in 110 previously untreated prepubertal children with growth hormone deficiency, of whom 86 were evaluable. Children received 30 micrograms/kg subcutaneously at bedtime [5].

Mean height velocity rose from 4.1 cm per year at baseline to 8.0 cm per year at 6 months and 7.2 cm per year at 12 months, and 74 percent of children were good responders at 6 months. No adverse changes appeared in general biochemical or hormonal tests, fasting glucose did not change, IGF-I was not excessively raised, and the drug was well tolerated overall [5]. Height velocity in children is a growth endpoint, not a recovery endpoint, and this study did not examine healing, muscle function or return to activity.

Two weeks in older men

Ten healthy older men with a mean age of 68 received 0.5 mg and 1 mg GHRH(1-29) subcutaneously twice daily for 14 days each, in random order, and were compared with nine young men with a mean age of 26. At the higher dose, 24-hour growth hormone and IGF-I rose to levels not significantly different from the young men [6]. This 14-day study measured hormone levels, not recovery or other clinical benefits [6].

Six weeks in older men

Eleven healthy, ambulatory, non-obese men aged 64 to 76 with low baseline IGF-I self-injected 2 mg GHRH nightly for 6 weeks [7]. Nocturnal growth hormone release increased (P<.02), as did the area under the growth hormone peak (P<.006) and peak amplitude (P<.05). IGF-I, IGFBP-3 and GH binding protein did not change. Two of six strength measures improved — upright row (P<.02) and shoulder press (P<.04) — as did an abdominal crunch endurance test (P<.03). Body composition by DEXA, muscle histology, and glucose and insulin responses during an oral glucose tolerance test did not change [7].

This was 11 men over 6 weeks, measured before and after treatment. It was not a recovery trial.

Doses used in studies are not recommended doses

No sermorelin product is currently FDA-approved, so there is no current approved dose [4][10]. Three doses appear in the published human data: 30 micrograms/kg once daily subcutaneously at bedtime in the pediatric program [5], 0.5 mg or 1 mg subcutaneously twice daily for 14 days in older men [6], and 2 mg nightly for 6 weeks in a second small study of older men [7]. These describe what investigators gave in specific studies. They are not recommended doses, and none was tested for recovery.

What was monitored

In the one-year pediatric study, the main outcomes were monitored every 3 to 6 months: linear growth, bone age progression and safety measures including clinical chemistry [5]. The adult studies measured growth hormone and IGF-I [6][7].

IGF-I behaved differently across the adult studies. In 10 older men, 1 mg twice daily for 14 days raised IGF-I to levels similar to young men [6]. In 11 older men, 2 mg nightly for 6 weeks raised nocturnal growth hormone but left IGF-I unchanged [7]. These were small studies of hormone and strength measures in older men; none tested a recovery protocol.

Compounded sermorelin today

With Geref gone, sermorelin products sold in the United States are compounded, not FDA-approved. FDA does not review the safety, effectiveness or quality of compounded drugs before they are marketed [10]. HealthRX.com offers sermorelin by prescription as a compounded product.

On the regulatory side, sermorelin does not appear on FDA's list of bulk drug substances that may present significant safety risks when compounded [12]. On FDA's list of nominated bulk substances for outsourcing facilities, updated March 21, 2025, sermorelin acetate sits in category 1 (under evaluation) and carries the list's marker for substances that are components of FDA-approved drugs [13]. It does not appear in any category on FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, and it is not one of the six peptides named in HHS's October 2026 draft enforcement-discretion policy [14][15].

Sermorelin and drug testing in sport

WADA's 2026 Prohibited List names sermorelin in S2.2.4, which covers growth hormone releasing factors, GHRH and its analogues. It is prohibited at all times, in and out of competition, and S2 substances are non-Specified Substances [9]. It is also named in the 2027 List, in force from January 1, 2027 [16].

The bottom line

Sermorelin is a GHRH analogue that prompts the pituitary to release growth hormone [8]. The published human data show that it raises growth hormone and, at some doses, IGF-I, that it improved height velocity in children with growth hormone deficiency, and that it improved a few strength measures in a small six-week study of older men [5][6][7]. None of these studies measured healing after injury or surgery [5][6][7].